At Evestra Onkologia, we are dedicated to pioneering advancements in women's health. As a clinical-stage biopharmaceutical start-up based in Lodz, Poland, and a subsidiary of Evestra Inc. in the USA, our mission is to develop and commercialize innovative oncology treatments and solutions for proliferative diseases. Our team boasts a distinguished track record, especially in oncology, with a focus on creating new and effective therapies through strategic collaborations with leading Polish research institutions and CRO companies. Our latest includes milestone the initiation of Phase I clinical studies for our novel compound, EVE126, targeting endometriosis and uterine fibroids.